A daily pill combined with chemotherapy produced tumour shrinkage in about six in 10 patients with newly diagnosed metastatic pancreatic cancer in an early-phase trial, according to updated results announced by Revolution Medicines. The findings come from a 61-patient study and are encouraging, but do not yet show whether the combination works better than chemotherapy alone.
The drug, daraxonrasib, was given with gemcitabine and nab-paclitaxel. The company announced the results on November 19, ahead of a presentation by trial investigator Wungki Park at a cancer research symposium in Barcelona on November 20.
Responses in the trial
By the data cutoff on September 28, patients had been followed for a median of 18.3 months. The updated analysis reported a confirmed objective response rate of 60.7%: tumours shrank or disappeared in those patients. Complete responses were reported in 8.2% of the group. The disease control rate was 90.2%.
Median progression-free survival — the time before the disease worsened — was 12.8 months. The median duration of response was 11.1 months, while the estimated proportion of patients alive at 12 months was 76.6%.
Park, an oncologist at Memorial Sloan Kettering Cancer Center and an investigator in the trial, said the results were encouraging. He said the deeper responses and near doubling in the duration of disease control might eventually translate into longer survival.
Important limits
RMC-GI-102 was an open-label Phase 1/2 study, and it did not include a randomised group receiving chemotherapy alone. The results therefore cannot establish whether the combination improves survival compared with standard chemotherapy. The company said the safety profile was consistent with what had previously been observed for daraxonrasib and the chemotherapy drugs.
Doctors quoted by BBC News cautioned that the findings should not be seen as a cure. Longer studies are needed to determine whether patients achieve remission and how long any disease control lasts. Cancer Research UK called the findings the biggest leap forward in pancreatic cancer treatment in decades.
What comes next
A global Phase 3 trial, RASolute 303, is testing daraxonrasib both on its own and with gemcitabine and nab-paclitaxel against chemotherapy alone in patients receiving first-line treatment. It includes patients regardless of their tumour’s RAS genotype. The larger, randomised study is intended to provide a clearer comparison.
Daraxonrasib is already FDA-approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment, or who are not candidates for multi-drug systemic treatment, according to the company. The newly reported results concern its use with chemotherapy as a potential first-line option.




Comments
To comment, sign in or create an account. Sign in Create an account
No comments yet.